Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q1 2026 · 10-Q
Revenue$0.00$0.00— vs Q1 2025 Net Income-$43.77K-$43.77KN/M vs Q1 2025 EPS Diluted$0.00$0.00— vs Q1 2025 Operating Income-$60,271N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 5, 2026 · 35 d after period end